nach oben

Erschienen in:

22.06.2020 | Diagnostik in der Gastroenterologie | Fortbildung_CME

Gastrointestinale Blutung, Malabsorption, Entzündung

Eisenmangelanämie bei gastrointestinalen Erkrankungen ist multifaktoriell

verfasst von: Prof. Dr. med. Jürgen Stein, Karima Farrag

Erschienen in: Gastro-News | Ausgabe 3/2020

Einloggen, um Zugang zu erhalten

Auszug

Die Entstehung des Eisenmangels und der Eisenmangelanämie bei gastrointestinalen Erkrankungen ist multifaktoriell. Zugrunde liegen oft kombiniert vermehrter Eisenverlust durch gastrointestinale Blutungen, eine Malabsorption des Eisens über die geschädigte Mukosa des Duodenums und/oder als Folge einer erhöhten Entzündungsaktivität im Sinne einer "Anämie chronisch entzündlicher Erkrankungen" sowie durch postoperative Zustände. …

Farrag K, Stein J. Eisenmangel - Bedeutung für die Gastroenterologie. Kompendium Gastroenterologie 2018;14:73-81

Stein J, Hartmann F, Dignass AU. Diagnosis and management of iron deficiency anemia in patients with IBD. Nat Rev Gastroenterol Hepatol 2010;7(11):599-610

Agarwal R. Nonhematological benefits of iron. American journal of nephrology 2007;27(6):565-71

Pratt JJ, Khan KS. Non-anaemic iron deficiency - a disease looking for recognition of diagnosis: a systematic review. Eur J Haematol 2016;96(6):618-28

Ganz T. Anemia of Inflammation. The New England journal of medicine 2019;381(12):1148-57

Aksan A, Wohlrath M, Iqbal TH, Dignass A, Stein J. Inflammation, but Not the Underlying Disease or Its Location, Predicts Oral Iron Absorption Capacity in Patients With Inflammatory Bowel Disease. J Crohns Colitis 2020;14(3):316-22

Dignass A, Farrag K, Stein J. Limitations of Serum Ferritin in Diagnosing Iron Deficiency in Inflammatory Conditions. Int J Chronic Dis 2018;2018:9394060

Cappellini MD, Comin-Colet J, de Francisco A et al. Iron deficiency across chronic inflammatory conditions: International expert opinion on definition, diagnosis, and management. Am J Hematol 2017;92(10):1068-78

Heimpel H, Diem H, Nebe T. [Counting reticulocytes: new importance of an old method]. Medizinische Klinik 2010;105(8):538-43

10.

Martin J, Radeke HH, Dignass A, Stein J. Current evaluation and management of anemia in patients with inflammatory bowel disease. Expert Rev Gastroenterol Hepatol 2017;11(1):19-32

11.

Dresow B, Petersen D, Fischer R, Nielsen P. Non-transferrin-bound iron in plasma following administration of oral iron drugs. Biometals 2008;21(3):273-6

12.

Hutchinson C, Al-Ashgar W, Liu DY, Hider RC, Powell JJ, Geissler CA. Oral ferrous sulphate leads to a marked increase in pro-oxidant nontransferrin-bound iron. Eur J Clin Invest 2004;34(11):782-4

13.

Brissot P, Ropert M, Le Lan C, Loreal O. Non-transferrin bound iron: a key role in iron overload and iron toxicity. Biochimica et biophysica acta 2012;1820(3):403-10

14.

Jaeggi T, Kortman GA, Moretti D, et al. Iron fortification adversely affects the gut microbiome, increases pathogen abundance and induces intestinal inflammation in Kenyan infants. Gut 2015;64(5):731-42

15.

Büning C, Stein J. Eisen(III)-Maltol: Ein neu zugelassenes dreiwertiges Eisenpräpart zur oralen Behandlung der Eisenmangelanämie bei erwachsenen Patienten mit CED. Drug Report 2017;9(7):1-12

16.

Yilmaz B, Li H. Gut Microbiota and Iron: The Crucial Actors in Health and Disease. Pharmaceuticals 2018;11(4)

17.

Tay HS, Soiza RL. Systematic review and metaanalysis: what is the evidence for oral iron supplementation in treating anaemia in elderly people? Drugs & aging 2015;32(2):149-58

18.

Cancelo-Hidalgo MJ, Castelo-Branco C, Palacios S, et al. Tolerability of different oral iron supplements: a systematic review. Curr Med Res Opin 2013;29(4):291-303

19.

Stein J, Haas JS, Ong SH, et al. Oral versus intravenous iron therapy in patients with inflammatory bowel disease and iron deficiency with and without anemia in Germany - a real-world evidence analysis. Clinicoecon Outcomes Res 2018;10:93-103

20.

Farrag K, Lipp HP, Stein J. Neue Optionen der oralen Eisensubstitution. AMT 2019;37:105-12

21.

Harvey RS, Reffitt DM, Doig LA, et al. Ferric trimaltol corrects iron deficiency anaemia in patients intolerant of iron. Aliment Pharmacol Ther 1998;12(9):845-48

22.

Gasche C, Ahmad T, Tulassay Z, et al. Ferric maltol is effective in correcting iron deficiency anemia in patients with inflammatory bowel disease: results from a phase-3 clinical trial program. Inflamm Bowel Dis 2015;21(3):579-88

23.

Schmidt C, Ahmad T, Tulassay Z, et al. Ferric maltol therapy for iron deficiency anaemia in patients with inflammatory bowel disease: long-term extension data from a Phase 3 study. Aliment Pharmacol Ther 2016;44(3):259-70

24.

Gomez-Ramirez S, Brilli E, Tarantino G, Munoz M. Sucrosomial((R)) Iron: A New Generation Iron for Improving Oral Supplementation. Pharmaceuticals 2018;11(4):97

25.

Fabiano A, Brilli E, Mattii L, et al. Ex Vivo and in Vivo Study of Sucrosomial((R)) Iron Intestinal Absorption and Bioavailability.IInt J Mol Sci 2018;19(9):2722

26.

Pisani A, Riccio E, Sabbatini M, Andreucci M, Del Rio A, Visciano B. Effect of oral liposomal iron versus intravenous iron for treatment of iron deficiency anaemia in CKD patients: a randomized trial. Nephrol Dial Transplant 2015;30(4):645-52

27.

Mafodda A, Giuffrida D, Prestifilippo A, et al. Oral sucrosomial iron versus intravenous iron in anemic cancer patients without iron deficiency receiving darbepoetin alfa: a pilot study. Supportive care in cancer : official journal of the Multinational Association of Supportive Care Cancer 2017;25(9):2779-86

28.

Parisi F, Berti C, Mando C, Martinelli A, Mazzali C, Cetin I. Effects of different regimens of iron prophylaxis on maternal iron status and pregnancy outcome: a randomized control trial. The journal of maternal-fetal & neonatal medicine: the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstet 2017;30(15):1787-92

29.

Camaschella C. Iron-deficiency anemia. N Engl J Med 2015;372(19):1832-43

30.

Moretti D, Goede JS, Zeder C, et al. Oral iron supplements increase hepcidin and decrease iron absorption from daily or twice-daily doses in iron-depleted young women. Blood 2015;126(17):1981-89

31.

Stoffel NU, Zeder C, Brittenham GM, Moretti D, Zimmermann MB. Iron absorption from supplements is greater with alternate day than with consecutive day dosing in iron-deficient anemic women. Haematologica 2019 Aug 14;haematol.2019.220830.

32.

Stein J, Aksan A, Farrag K, Dignass A, Radeke HH. Management of inflammatory bowel disease-related anemia and iron deficiency with specific reference to the role of intravenous iron in current practice. Expert Opin Pharmacother 2017;18(16):1721-37

33.

Okam MM, Koch TA, Tran MH. Iron Supplementation, Response in Iron-Deficiency Anemia: Analysis of Five Trials. Am J Med 2017 Aug;130(8):991.e1-991.e8.

34.

Aksan A, Farrag K, Stein J. An update on the evaluation and management of iron deficiency anemia in inflammatory bowel disease. Expert Rev Gastroenterol Hepatol 2019;13(2):95-7

35.

Aksan A, Isik H, Radeke HH, Dignass A, Stein J. Systematic review with network metaanalysis: comparative efficacy and tolerability of different intravenous iron formulations for the treatment of iron deficiency anaemia in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2017;45(10):1303-18

36.

Gozzard D. When is high-dose intravenous iron repletion needed? Assessing new treatment options. Drug design, development and therapy 2011;5:51-60

37.

Evstatiev R, Marteau P, Iqbal T et al. FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease. Gastroenterology 2011;141(3):846-53 e841-42

38.

Dignass AU, Gasche C, Bettenworth D et al. European consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases. J Crohns Colitis 2015;9(3):211-22

39.

Evstatiev R, Alexeeva O, Bokemeyer B et al. Ferric carboxymaltose prevents recurrence of anemia in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2013;11(3):269-77

40.

Nikravesh N, Borchard G, Hofmann H, Philipp E, Fluhmann B, Wick P. Factors influencing safety and efficacy of intravenous iron-carbohydrate nanomedicines: From production to clinical practice. Nanomedicine 2020;26:102178

41.

Avni T, Bieber A, Grossman A, Green H, Leibovici L, Gafter-Gvili A. The safety of intravenous iron preparations: systematic review and meta-analysis. Mayo Clin Proc 2015;90(1):12-23

42.

Aksan A, Işık H, Aksan S, Tuğal D, Dignass A, Stein JM. Evaluation and comparison of the safety profiles of different intravenous iron preparations and oral iron for treatment of iron deficiency anaemia: Preliminary results from the IBD subgroup analysis. J Crohn Colitis 2020;14/S1:490

43.

Bager P, Hvas CL, Dahlerup JF. Drug-specific hypophosphatemia and hypersensitivity reactions following different intravenous iron infusions. British journal of clinical pharmacology 2017;83(5):1118-25

44.

Wolf M, Rubin J, Achebe M et al. Effects of Iron Isomaltoside vs Ferric Carboxymaltose on Hypophosphatemia in Iron-Deficiency Anemia: Two Randomized Clinical Trials. JAMA. 2020;323(5):432-43

45.

Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med 2005;352(10):1011-23

46.

Brock JH et al. (eds) Iron Metabolism in Health Disease. Saunders (W.B.) Co Ltd 1994

47.

Geisser P et al. Drug Res 1992;42(II),12:1439-52

48.

Stein J, Connor S, Virgin G, Ong DE, Pereyra L. Anemia and iron deficiency in gastrointestinal and liver conditions. World J Gastroenterol 2016;22:7908-25

Titel: Gastrointestinale Blutung, Malabsorption, Entzündung
Eisenmangelanämie bei gastrointestinalen Erkrankungen ist multifaktoriell
verfasst von: Prof. Dr. med. Jürgen Stein
Karima Farrag
Publikationsdatum: 22.06.2020
Verlag: Springer Medizin
Schlagwörter: Diagnostik in der Gastroenterologie
Eisenmangelanämie
Duodenalulkus
Nebenwirkungen
Magenulkus
Zöliakie
Infektiöse Erkrankungen des Magen-Darm-Traktes
Chronisch-entzündliche Darmerkrankungen
Hämatologische Erkrankungen in der Hausarztpraxis
Gastrointestinale Erkrankungen in der Hausarztpraxis
Erschienen in: Gastro-News / Ausgabe 3/2020
Print ISSN: 1869-1005
Elektronische ISSN: 2520-8667
DOI: https://doi.org/10.1007/s15036-020-1322-9

Magen-Darm-Erkrankungen in der Hausarztpraxis

Häufige gastrointestinale Krankheiten in der niedergelassenen Praxis sind Thema in diesem aufgezeichneten MMW-Webinar. Welche Differenzialdiagnosen bei Oberbauchbeschwerden sollten Sie kennen? Wie gelingt eine erfolgreiche probiotische Behandlung bei Reizdarm? Welche neuen Entwicklungen und praktischen Aspekte gibt es bei Diagnostik und Behandlung der chronisch entzündlichen Darmerkrankungen?

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Auszug

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2020

Ein Nachruf - Trauer um Dr. Gerhard Brenner

Helicobacter-pylori-Eradikation bei Verwandten von Magenkrebspatienten von Vorteil?

Neue Kombinationstherapie für Patienten mit BRAF-Mutation

Die aktuellen Studien zu Kolon, Mikrobiom und CED

Alles Corona - oder was?

infopharm

Magen-Darm-Erkrankungen in der Hausarztpraxis